Pemivibart is under clinical development by Invivyd and currently in Phase III for Non-Hodgkin Lymphoma. According to GlobalData, Phase III drugs for Non-Hodgkin Lymphoma have a 58% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Pemivibart’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pemivibart overview
Pemivibart (Pemgarda) is a half-life extended monoclonal antibody (mAb). It is formulated as powder for solution for administration as intravenous infusion. Pemgarda is indicated for the pre-exposure prophylaxis (prevention) of Covid-19 in adults and adolescents (12 years of age and older weighing at least 40 kg) who have moderate-to-severe immune compromise due to certain medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID-19 vaccination. It is being developed based on NVYMAB platform.
VYD-222 is under development for the prevention and treatment of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) including the KP.1.1 FLiRT and KP.3 variants, chronic lymphocytic leukemia (CLL), acute leukemia, non-Hodgkin lymphoma, or multiple myeloma. The drug candidate is a monoclonal antibody which is a re-engineered version of adintrevimab (ADG20). It is administered through intravenous route.
Invivyd overview
Invivyd, formerly Adagio Therapeutics, is a biopharmaceutical company that discovers, develops and commercializes antibody-based solutions for infectious disease. It is investigating its lead product candidate ADG20, for the treatment and prevention of COVID-19. The company also evaluates ADG10, for use in combination with ADG20 to treat COVID-19; and preventative agents targeting additional coronaviruses, seasonal and pandemic influenza. Its approach focuses on neutralizing antibodies that target conserved epitopes across multiple members of coronavirus family. Invivyd is headquartered in Waltham, Massachusetts, the US.
For a complete picture of Pemivibart’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
